Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Product Contact Surface Management – V 2.0

Posted on By


Biosimilars: SOP for Product Contact Surface Management – V 2.0


Standard Operating Procedure for Product Contact Surface Management in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/194/2025
Supersedes SOP/BS/194/2022
Page No. Page 1 of 9
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a GMP-compliant procedure for the management, cleaning, inspection, and maintenance of product contact surfaces used in biosimilar manufacturing to ensure product integrity and safety.

2. Scope

This SOP applies to all vessels, tubing, fittings, and components that come into direct contact with biosimilar drug substance or intermediates during production, purification, or storage operations.

3. Responsibilities

  • Production: Execute cleaning and inspection of contact surfaces per batch requirement.
  • Engineering: Maintain integrity and surface finish of contact equipment.
  • QA: Review cleaning logs and surface inspection records; ensure compliance with cleaning validation.

4. Accountability

The Head of Manufacturing and Head of Engineering are jointly accountable for the control and validation of all product contact surfaces in compliance with GMP standards.

5. Procedure

5.1 Identification of Product Contact Surfaces

  1. List all parts of equipment and accessories that contact product or buffer solutions including:
    • Stainless steel vessels (grade 316L)
    • Tubing (silicone, TPE)
    • Filter housings, gaskets, sampling valves
  2. Update product contact component register (Annexure-1).

5.2 Cleaning and Sanitization

  1. Use validated cleaning procedures for each equipment type post-use.
  2. For stainless steel: perform CIP with alkaline/acid detergents followed by WFI rinses.
  3. For single-use systems: ensure visual cleanliness and proper disposal post-use.

5.3 Visual and Surface Integrity Checks

  1. Perform visual inspection under white light for:
    • Scratches, pitting, discoloration
    • Signs of corrosion or damage
  2. Perform boroscope examination for internal surfaces annually or post-cleaning validation failure.
  3. Record findings in Annexure-2.

5.4 Surface Roughness and Passivation

  1. Confirm surface finish of stainless steel parts is Ra ≤ 0.5 µm.
  2. Perform passivation (e.g., with nitric or citric acid) every 12 months or post-maintenance.
  3. Document passivation activity and results in Annexure-3.

5.5 Labeling and Status Management

  1. Label all equipment and parts post-cleaning as “CLEANED – PRODUCT CONTACT” with:
    • Date of cleaning
    • Time and initials
    • Next due date for cleaning/inspection

5.6 Deviation and Requalification

  1. Report damage or non-conformance to QA and Engineering immediately.
  2. Requalify surface integrity post-repair, maintenance, or replacement before reuse.

6. Abbreviations

  • CIP: Clean-in-Place
  • Ra: Surface Roughness Average
  • QA: Quality Assurance
  • WFI: Water for Injection

7. Documents

  1. Product Contact Component Register – Annexure-1
  2. Surface Inspection Checklist – Annexure-2
  3. Passivation Record – Annexure-3

8. References

  • ASME BPE Standards for Bioprocessing Equipment
  • FDA Guidance on Equipment Cleaning and Maintenance
  • WHO TRS 999 – GMP Guidelines for Biotherapeutics

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Product Contact Component Register

Equipment ID Component Material Last Cleaned Status
BX-401 Dip Tube SS316L 04/05/2025 Cleaned

Annexure-2: Surface Inspection Checklist

Equipment ID Inspected Area Observation Inspector Date
BX-401 Inner Wall No defects Ajay Verma 04/05/2025

Annexure-3: Passivation Record

Date Equipment ID Agent Used Contact Time (min) Result Performed By
01/03/2025 BX-401 20% Nitric Acid 30 Pass Sunita Reddy

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded to include single-use system references and surface passivation tracking Process harmonization
See also  Biosimilars: SOP for Removal of Host Cell Proteins - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Failure to Brief Staff on SOPs Ahead of Inspection: A Risk to GMP Audit Readiness
Next Post: Gel Manufacturing: SOP for Manufacturing Gels with Sustained Release Properties – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version